PURE Bioscience reports FY2023 net loss of $4.0M, revenue up slightly; Q4 revenue jumps 49% YoY

PURE BIOSCIENCE, INC.

Net product sales $1.871M vs $1.813M prior year (+3.2%); net loss widened to $4.0M from $3.5M.
Cash used in operations increased to $3.3M from $2.5M; net loss per share unchanged at ($0.04).
Q4 revenue increased 49% YoY; CEO sees turning point and confirms new customer-driven programs.
Company moving to all-remote work model, closing Rancho Cucamonga facility to reduce costs.
Introduced 'PURE GENIUS' food safety solution at IAFP conference; now in multiple food processing facilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PURE BIOSCIENCE, INC. reported financial results for fiscal year ended July 31, 2023.

Period: fiscal year ended July 31, 2023
Result: reported results

Exact text from the filing

On October 30, 2023, PURE Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year ended July 30, 2023 and related information.

View on SEC.gov

Browse all earnings releases →

PURE BIOSCIENCE, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-038669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.